Literature DB >> 11035380

The worldwide prevalence and epidemiology of erectile dysfunction.

J B McKinlay1.   

Abstract

This paper: (i) describes the worldwide prevalence of erectile dysfunction (ED); (ii) presents age-specific incidence rates for ED in the US; (iii) summarizes some key epidemiologic correlates of ED in the general population; and (iv) considers the possibility that ED may be a biobehavioral marker (sentinel event) of subsequent cardiovascular disease in men. Clinical, anthropometric, life style and hormonal data are presented from the milestone Massachusetts Male Aging Study (MMAS), a large (over 1000) prospective cohort of randomly sampled community-dwelling, normally aging men. Newly updated population prevalence and (more importantly) age-specific incidence rates are reported. We also estimate the likely magnitude of ED that will accompany the worldwide globalization of aging. Key correlates (predictors) of incident ED, especially vasculogenic influences, are identified and discussed. In conclusion, ED is a common biobehavioral phenomenon and there are strong physiological and epidemiological reasons for considering it a major marker (or predictor) of subsequent cardiovascular disease in men. International Journal of Impotence Research (2000) 12, Suppl 4, S6-S11.

Entities:  

Mesh:

Year:  2000        PMID: 11035380     DOI: 10.1038/sj.ijir.3900567

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  59 in total

1.  Sex and the single (older) guy: sexual lives of older unmarried Thai men during the AIDS era.

Authors:  Mark Vanlandingham; John Knodel
Journal:  J Cross Cult Gerontol       Date:  2007-12

2.  Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.

Authors:  Steven A Kaplan; Ricardo R Gonzalez
Journal:  Rev Urol       Date:  2007

3.  In vitro and in vivo studies on the importance of the soluble guanylyl cyclase α1 subunit in penile erection.

Authors:  Kelly Decaluwé; Sofie Nimmegeers; Robrecht Thoonen; Emanuel Buys; Peter Brouckaert; Johan Van de Voorde
Journal:  World J Urol       Date:  2010-01-23       Impact factor: 4.226

Review 4.  Combination therapy for erectile dysfunction: an update review.

Authors:  Rohit R Dhir; Hao-Cheng Lin; Steven E Canfield; Run Wang
Journal:  Asian J Androl       Date:  2011-03-21       Impact factor: 3.285

Review 5.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

6.  A population-based, longitudinal study of erectile dysfunction and future coronary artery disease.

Authors:  Brant A Inman; Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Ajay Nehra; Michael M Lieber; Véronique L Roger; Steven J Jacobsen
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

Review 7.  Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.

Authors:  Ajay Nehra
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

8.  Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study.

Authors:  Dong Hyuk Kang; Joo Yong Lee; Sung Yul Park; Hong Sang Moon; Tae Yoong Jeong; Tag Keun Yoo; Hong Yong Choi; Hae Young Park; Tchun Yong Lee; Seung Wook Lee
Journal:  Korean J Urol       Date:  2010-09-17

9.  Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study.

Authors:  M T Rosenberg; P L Adams; T A McBride; J N Roberts; S W McCallum
Journal:  Int J Clin Pract       Date:  2009-01       Impact factor: 2.503

Review 10.  Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence.

Authors:  Antonio Martín Morales; Vincenzo Mirone; John Dean; Pierre Costa
Journal:  Clin Interv Aging       Date:  2009-12-29       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.